USA News Group News
Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, April 29,
2025 /PRNewswire/ -- Artificial intelligence is
making deeper inroads into western healthcare, targeting the slow
grind of authorizations and paperwork that bog down patient care.
Despite Bill Gates' prophecy about
AI replacing doctors, the real push today is about supercharging
physicians, not sidelining them. Recent moves by players such as
like Avant Technologies, Inc. (OTCQB: AVAI), Amesite
Inc. (NASDAQ: AMST), Oracle Corporation (NYSE: ORCL),
Clover Health Investments, Corp. (NASDAQ: CLOV), and
Alphabet Inc. (NASDAQ: GOOG, GOOGL) are signaling just how
fast this transformation is taking hold.
The article continued: Meanwhile, Barclays projects
the healthcare AI market will surge at a 30% compound annual growth
rate through 2030, fueled by a wave of new investment across
hospitals, insurers, and pharma. A Deloitte survey echoes
the optimism, with 71% of healthcare leaders expecting better
profits this year as AI tools scale across systems.
Avant Technologies and Ainnova Request Pre-Submission Meeting
with US FDA for VisionAI Platform Technology
Avant Technologies, Inc. (OTCQB: AVAI), an emerging
leader in AI-driven healthcare innovation, and its JV partner,
Ainnova Tech, Inc., (Ainnova), a leading healthcare
technology company focused on revolutionizing early disease
detection using artificial intelligence (AI), today announced that
The Center for Devices and Radiological Health of the U.S. Food
and Drug Administration (FDA) has received the company's
submission package requesting a pre-submission meeting with the
FDA for its VisionAI platform technology and is now under
review.
Ainnova is requesting a pre-submission meeting with the
FDA's review team to discuss any questions and/or concerns
about its proposed formal submission, including seeking advice to
finalize the protocol and obtain agency guidance for a clinical
trial of its VisionAI platform in the early detection of diabetic
retinopathy. A pre-submission meeting allows companies to clarify
regulatory requirements, get feedback on their plans, and
potentially avoid delays or issues during the formal review
process.
The clinical studies will aim to support an FDA 510(k)
submission to obtain clearance from the regulatory agency to market
its technology in the U.S.
Ai-nova Acquisition Corp. (AAC), the company formed by
the partnership between Avant and Ainnova to advance
and commercialize Ainnova's technology portfolio, including
its VisionAI platform and its versatile retinal cameras, has
worldwide licensing rights for this portfolio. The licensing rights
include the U.S., where the FDA regulates drug and medical device
development, so the success of Ainnova's interactions with
the FDA are paramount to marketing the technology portfolio
in the United States.
"This milestone reflects our two-tiered strategy, rapid
deployment in low-regulation markets where VisionAI operates as a
screening tool, and simultaneous progress toward FDA
clearance for the U.S. market," said Vinicio Vargas, CEO at Ainnova and a
member of AAC's Board of Directors. "Entering the U.S. will
unlock significant commercial potential, and early engagement with
regulators ensures we do so with speed, credibility, and a
validated product."
For medical device applicants like Ainnova, the FDA's
pre-submission program is useful to determine a clear regulatory
pathway for the successful launch of the device, including
the number of patients and the number of clinics that will be
needed to generate the necessary clinical data for the FDA
to make an informed decision on Ainnova's VisionAI
platform.
For Avant, the pre-submission meeting will help define a
precise budget for the strategic partnership's entire FDA
process.
This follows Ainnova's recent strategic alignment with
Apollo Hospitals in Southeast
Asia, where the Vision AI platform has been cleared for
commercial deployment in Brazil,
and clinical pilots are being prepared across the Americas.
Avant and Ainnova have identified Brazil and the
United States as key strategic markets. Ainnova is
currently addressing regulatory pathways in Brazil with the support of its MDSAP
certification to meet ANVISA requirements, paving the way
for rapid market entry.
Ainnova is being guided by global CRO Fortrea
ahead of the important pre-submission meeting with the FDA.
The goal is to seek 510(k) clearance for Vision AI in detecting
diabetic retinopathy, a gateway to broader use across multiple
chronic disease categories.
Between FDA progress, high-profile alliances, and a
growing international presence, Avant Technologies continues
to carve out a niche in the convergence of AI, diagnostics, and
preventative care. Investors looking for small-cap exposure to the
healthcare AI revolution may want to keep AVAI on the radar
as these developments unfold.
CONTINUED… Read this and more news for Avant Technologies
Inc.
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Amesite Inc. (NASDAQ: AMST) recently extended HIPAA
compliance for its NurseMagic™ platform to cover individual users
as well as enterprise clients. Healthcare providers can now safely
use NurseMagic™ to store patient data, helping to reduce
documentation time while protecting sensitive information.
"Meeting HIPAA requirements for all of our users is a natural
extension of what we've already provided to enterprise customers,"
said Kalie Wortinger, Senior Manager
of Engineering at Amesite. "We operate in a highly regulated
industry, where protecting sensitive data is essential. This
expansion reinforces our commitment to trust, privacy, and
long-term value—for individual users, organizations, and their
patients."
The platform's flexibility allows users to integrate
AI-generated notes into any existing electronic medical record
system.
Oracle Corporation (NYSE: ORCL) recently revealed that
North York General Hospital is the first hospital in
Canada to migrate its electronic
health record system to Oracle Cloud Infrastructure (OCI). The move
has significantly decreased system latency, improved login and
transaction times, and enhanced disaster recovery protections.
"North York General Hospital is on a mission to set new
standards for people-centered care through integrated and
coordinated patient services across the organization, and its
recent migration to OCI provides the foundation required to achieve
that goal," said Erin O'Halloran,
vice president and Canada market
leader, Oracle Health. "Leveraging OCI's regional footprint
in Canada to store and process
data has helped NYGH bolster its resilience, improve its
scalability, and helped it implement strategic approaches to
disaster recovery."
These upgrades are helping clinicians work more efficiently and
spend more time with patients. By leveraging OCI, NYGH is
positioning itself to advance innovation in healthcare through
real-time data and AI technologies.
Clover Health Investments, Corp. (NASDAQ: CLOV) recently
announced that its subsidiary, Counterpart Health, is
partnering with Alphabet Inc. (NASDAQ: GOOG, GOOGL) through
Google Cloud to enhance its Counterpart Assistant
platform.
"Physicians are often under-resourced and lack access to
cutting-edge technologies that can simplify care delivery," said
David Tsay, MD, chief medical
officer at Counterpart. "Our goal with Counterpart Assistant
is to bring all the leading edge tools under one roof, layer them
over a single source of normalized data, and give clinicians what
they need to make informed decisions—without the burden of
fragmented solutions."
By integrating Google Cloud's Vertex AI Search, the
platform enables physicians to quickly access unified patient
records and receive AI-generated clinical insights. The
collaboration is designed to streamline clinical workflows, reduce
administrative burdens, and support better outcomes in value-based
care.
"Clinicians are spending nearly 28 hours a week on
administrative tasks, and 82% are reporting burnout," said
Aashima Gupta, global director of
Healthcare Strategy & Solutions, Google Cloud. "Gen
AI-powered search can help alleviate some of this burden, and
Counterpart Health's integration of Vertex AI Search will
empower physicians to access critical patient information quickly
and efficiently, helping them refocus on what matters most: better
patient care."
Source:
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Avant Technologies Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares Avant Technologies Inc., and may liquidate their shares
which could have a negative effect on the price of the stock. This
compensation constitutes a conflict of interest as to our ability
to remain objective in our communication regarding the profiled
company. Because of this conflict, individuals are strongly
encouraged to not use this publication as the basis for any
investment decision. The owner/operator of MIQ own shares of Avant
Technologies Inc. which were purchased in the open market. MIQ
reserves the right to buy and sell, and will buy and sell shares of
Avant Technologies Inc. at any time thereafter without any further
notice. We also expect further compensation as an ongoing digital
media effort to increase visibility for the company, no further
notice will be given, but let this disclaimer serve as notice that
all material disseminated by MIQ has been approved by the above
mentioned company; this is a paid advertisement, and we own shares
of the mentioned company that we will sell, and we also reserve the
right to buy shares of the company in the open market, or through
other investment vehicles. While all information is believed to be
reliable, it is not guaranteed by us to be accurate. Individuals
should assume that all information contained in our newsletter is
not trustworthy unless verified by their own independent research.
Also, because events and circumstances frequently do not occur as
expected, there will likely be differences between any predictions
and actual results. Always consult a licensed investment
professional before making any investment decision. Be extremely
careful, investing in securities carries a high degree of risk; you
may likely lose some or all of the investment.
Logo:
https://mma.prnewswire.com/media/2603685/5292786/USA_News_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/new-advances-in-healthcare-ai-could-unlock-billions-in-market-opportunity-302441469.html
